News

Exciting Phase 3 Results for Dupixent in Chronic Urticaria

Exciting Phase 3 Results for Dupixent in Chronic Urticaria

Promising Phase 3 Findings for Dupixent in Treating Chronic Urticaria

Dupixent showed significant reductions in itch and hive severity; 41% of patients reached well-controlled disease status.

Supporting data for potential U.S. regulatory resubmission anticipated by year-end; if approved, Dupixent could be the first new targeted therapy for chronic spontaneous urticaria in over a decade.

Over 300,000 people in the U.S. are affected by chronic spontaneous urticaria, which is often poorly managed by antihistamines.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi recently reported encouraging results from the Phase 3 LIBERTY-CUPID Study C. This study investigated Dupixent's effectiveness in treating biologic-naïve patients with uncontrolled chronic spontaneous urticaria (CSU), who also received standard treatment with antihistamines. The outcome demonstrated that Dupixent led to a notable decrease in itch and urticaria activity scores compared to placebo, with a considerable number of patients achieving better disease control. The results are set to be presented at the esteemed American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting.

Dr. Thomas B. Casale, a respected professor of Internal Medicine, emphasized the burdens of chronic spontaneous urticaria, which often entails unpredictable episodes of intense itching and hives, affecting the quality of life of those suffering from it. He remarked, "These data confirm earlier findings and highlight Dupixent's potential in alleviating symptoms for patients, which could significantly improve their ability to manage this challenging condition."

The LIBERTY-CUPID Study C included a total of 151 participants, consisting of both adults and children. They were randomly assigned to receive either Dupixent or placebo, alongside standard H1 antihistamine therapy. After a 24-week treatment period, Dupixent displayed noteworthy improvements in several key metrics in comparison to placebo:

Key Findings from the Study

  • Decrease in itch severity score: a reduction of 8.64 points for Dupixent versus 6.10 points for placebo (p=0.02).
  • Urticaria (itch and hive) activity score: a notable decrease of 15.86 points with Dupixent compared to 11.21 points for placebo (p=0.02).
  • 41% of Dupixent patients achieved well-controlled disease status (urticaria activity score ? 6) compared to 23% in the placebo group (p=0.005).
  • Complete response rate (urticaria activity score = 0): 30% for Dupixent versus 18% for placebo (p=0.02).

The safety profile observed in Study C was consistent with prior findings related to Dupixent in its approved dermatological applications. The overall incidence of treatment-emergent adverse events (AEs) was equivalent at 53% for both Dupixent and placebo groups. Common AEs observed with Dupixent (?5%) included injection site reactions (12% vs. 4%), accidental overdose (7% vs. 3%), and COVID-19 infection (8% vs. 5%).

Dupixent is already approved for use in chronic spontaneous urticaria in Japan and the UAE, with ongoing regulatory evaluations in the European Union based on earlier trial outcomes. However, outside of these regions, Dupixent's safety and efficacy for CSU continue to await comprehensive assessment by health authorities.

Insights on Chronic Spontaneous Urticaria and Dupixent

Chronic spontaneous urticaria (CSU) is marked by sudden hives and persistent itching, often stemming from type 2 inflammation. H1 antihistamines are conventionally used to manage symptoms, yet many patients remain symptomatic despite such treatments, leaving them with limited therapeutic options that can significantly affect their quality of life. In the U.S. alone, over 300,000 individuals are living with CSU inadequately managed by antihistamines.

Understanding Dupixent’s Role in Treatment

Dupixent, an innovative treatment developed through Regeneron’s proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the IL-4 and IL-13 signaling pathways effectively. This mechanism of action is crucial in mitigating type 2 inflammation that is often involved in chronic allergic conditions. Dupixent has demonstrated remarkable clinical benefits across various Phase 3 studies, solidifying its role in the treatment spectrum for CSU, as well as other related diseases.

Dupixent is approved in over 60 countries, and its indications span multiple conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD), treating over one million patients globally.

Regeneron's Commitment to Innovation

Regeneron is firmly positioned at the forefront of biotechnology, continuously innovating and developing new therapies to address serious health issues. The collaborative development of Dupixent with Sanofi underscores a commitment to leveraging scientific advancements in improving patient health outcomes. Regeneron’s VelocImmune technology effectively creates optimized antibodies, enabling the company to contribute significantly to the ongoing war against chronic inflammatory diseases.

As research continues and more data is gathered, the case for Dupixent as a transformative therapy in chronic spontaneous urticaria only strengthens. For patients seeking effective treatment options, ongoing developments provide hope for enhanced management of debilitating symptoms and improved overall quality of life.

Frequently Asked Questions

What condition is Dupixent primarily used to treat?

Dupixent is primarily used to treat chronic spontaneous urticaria and other conditions related to type 2 inflammation.

How does Dupixent work?

Dupixent inhibits the IL-4 and IL-13 signaling pathways, which are involved in the inflammatory process associated with various allergic diseases.

What were the results from the LIBERTY-CUPID Study C?

The study showed significant reductions in itch and hive severity, with 41% of patients achieving well-controlled disease status.

What is the safety profile of Dupixent?

Dupixent's safety profile is consistent with its known dermatological applications, with common AEs including injection site reactions and potential infections.

How many patients are currently on Dupixent worldwide?

More than 1,000,000 patients are being treated with Dupixent globally, reflecting its widespread use and acceptance in managing chronic conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 44

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 0

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 48

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 78

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 133

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 199

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 0

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

Marjorie Taylor Greene's Diverse Portfolio Emphasizes Growth

Updated Category News Views 243

Marjorie Taylor Greene's Investment Choices Marjorie Taylor Greene, a well-known congressional representative, is making headlines lately with her recent stock investments. Reports indicate that her investment decisions reflect a strong interest in diverse sectors, including technology, healthcare, and logistics. This varied approach highlights her strategic thinking as...

Continue Reading
RBB Bancorp's Incredible Third Quarter Gains and Dividend

Updated Category News Views 178

RBB Bancorp: A Review of Stellar Financial Performance RBB Bancorp, alongside its subsidiaries, has recently announced impressive financial results for the quarter ended September 30, 2025. In an era where financial stability is paramount, RBB Bancorp (NASDAQ:RBB) emerged with promising metrics indicating solid progress. Key Financial Highlights for Q3 2025 Net income...

Continue Reading
Hancock Whitney to Share Q3 2024 Results and Insights Soon

Updated Category News Views 69

Exciting News from Hancock Whitney Corporation Hancock Whitney Corporation (Nasdaq: HWC) is about to share its financial performance for the third quarter of 2024. This announcement will take place after the market closes, paving the way for an insightful conference call with both analysts and investors. Details on Financial Results and Conference Call The expected...

Continue Reading
GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales

Updated Category News Views 229

GunsAmerica Reinforces Leading Role in Safe Online Firearm Sales GunsAmerica stands at the forefront of the online firearm marketplace, continually evolving to ensure the utmost safety and security for its users. The platform has earned a stellar reputation over its impressive 28-year history by prioritizing secure firearm transactions and implementing robust measures...

Continue Reading
Acrivon Therapeutics Pushes Ahead with ACR-2316 Trials

Updated Category News Views 70

Exciting Milestone in Oncology Trials Acrivon Therapeutics, Inc. has recently reached a significant milestone by dosing its first patient in the Phase 1 clinical trial of ACR-2316. This innovative WEE1/PKMYT1 inhibitor was developed using Acrivon’s advanced AP3 platform, which accelerates the discovery and design of effective cancer treatments. The progress marks a...

Continue Reading